PT-141 Peptide: Dosage, Benefits, Side Effects & How It Works

Michael Phelps

Founder & Peptide Research Specialist, PrymaLab

Updated April 4, 2025 • 28 min read

What Is PT-141 Peptide?

PT-141 peptide is known in science as bremelanotide. It is a synthetic peptide — a cyclic heptapeptide, which means seven amino acids arranged in a ring. It belongs to the melanocortin family. Palatin Technologies developed it, and it was first described in 2003 (Molinoff et al., Ann N Y Acad Sci, 2003). It came out of research into melanocortin peptides. These signaling molecules derive from pro-opiomelanocortin (POMC). They regulate many body functions, including skin color, appetite, energy balance, and sexual behavior.

The compound carries CAS registry number 189691-06-3 and PubChem CID 9941379. These identifiers distinguish it in chemical databases worldwide.

The history of PT-141 involves a lucky discovery. That discovery changed the whole direction of the compound's clinical research. PT-141 was first studied as a synthetic tanning agent. As an α-MSH analog, it was designed to boost melanin and darken skin without UV exposure. During early testing in the late 1990s and early 2000s, researchers saw something unexpected. The effects of PT-141 on sexual arousal were pronounced in both men and women.

These findings first showed up as side effects in the tanning studies. They were so consistent that they redirected the whole program toward sexual dysfunction. That pivot led to one of the more unusual drug approvals in recent history. A failed cosmetic product became a first-in-class sexual desire medication.

On June 21, 2019, the U.S. Food and Drug Administration approved bremelanotide under the brand name Vyleesi. The approval covered acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It rested on two pivotal RECONNECT Phase 3 clinical trials in 1,267 women. That made PT-141 only the second FDA-approved drug for female sexual dysfunction, after flibanserin (Addyi) in 2015.

Flibanserin requires a daily oral pill. The approved form of PT-141 does not. It is an on-demand 1.75 mg subcutaneous PT-141 peptide injection delivered by an autoinjection pen. Users take it as needed, at least 45 minutes before expected sexual activity. This gives HSDD a very different treatment approach.

One thing sets PT-141 apart from nearly every other sexual dysfunction treatment: its central nervous system mechanism of action. PDE5 inhibitors like Viagra and Cialis target blood vessels to improve blood flow. Flibanserin adjusts serotonin receptors to slowly shift the desire baseline. PT-141 does neither. It activates melanocortin receptors in the brain — mainly MC4R receptors in the hypothalamus and limbic system. This directly modulates the pathways that control sexual desire and arousal.

In short, PT-141 addresses the psychological and neurological roots of sexual dysfunction, not just the physical mechanics. This makes it useful where desire itself is low, not only where physical response is impaired. For researchers in sexual health and neuroscience, PT-141 is a unique tool. It helps show how the melanocortin system shapes human sexual behavior.

PT-141 Peptide: Chemical Structure and Properties

The chemical structure of PT-141 explains a lot. It shapes how the compound binds receptors, how stable it is, and how it behaves in the body. Bremelanotide is a cyclic lactam heptapeptide. That means seven amino acids form a ring, closed by a lactam (amide) bond between two side chains.

This ring is the key to its activity. The cyclization locks the peptide into a fixed shape. That shape mimics the active form of natural α-MSH and boosts binding to melanocortin receptors.

The amino acid sequence of PT-141 is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. Here Ac is an acetyl cap on the N-terminus. Nle is norleucine, a non-natural amino acid that improves oxidative stability. D-Phe is the D-form of phenylalanine, which resists enzyme breakdown. The ring closes between the aspartate (Asp) and lysine (Lys) side chains. This 23-membered ring limits movement and sharply increases binding selectivity over the linear parent peptide α-MSH. The molecular formula is C₅₀H₆₈N₁₄O₁₀, and the molecular weight is about 1,025 Da for the free base.

Structural Comparison with Related Melanocortins

PT-141 comes from Melanotan II (MT-II). MT-II is another synthetic peptide melanocortin analog first made as a tanning agent. The main difference is simple. PT-141 lacks the amide extension on MT-II's acetyl-norleucine residue. As a result, it behaves differently in the body, even though both share the same core cyclic pharmacophore.

Both compounds activate melanocortin receptors. PT-141 was chosen for clinical development for two reasons: a better pharmacokinetic profile, and the ability to be made for on-demand subcutaneous use. The line from α-MSH to Melanotan II to PT-141 shows a steady refinement of melanocortin pharmacology. It moves from a linear natural peptide toward tuned synthetic analogs with better receptor selectivity and stability.

The research-grade powder is white to off-white and freeze-dried. It dissolves easily in water and bacteriostatic water, so reconstitution is simple. The cyclic structure resists enzymes better than linear peptides. That is why it has 100% subcutaneous bioavailability and a 2.7-hour plasma half-life. These traits suit on-demand use, so it does not need constant infusion or frequent dosing.

How Does PT-141 Work? The Melanocortin Receptor Mechanism

To see how PT-141 works, start with the melanocortin system. This network of receptors and peptides evolved to regulate some of the body's most basic drives: appetite, energy balance, inflammation, and sexual behavior. There are five receptor subtypes, MC1R through MC5R. Each sits in different tissues and does different jobs. Bremelanotide activates several of them, in this order of potency: MC1R > MC4R > MC3R > MC5R > MC2R (FDA Label, 2019).

This multi-receptor profile explains both the good and the bad. The sexual effects come mainly through MC4R. The PT-141 side effects come elsewhere. Nausea may come through MC3R/MC4R in the brainstem. Skin darkening comes through MC1R in melanocytes.

MC4R: The Sexual Desire Receptor

The melanocortin-4 receptor (MC4R) is thought to drive PT-141's sexual effects. MC4R is found widely in the central nervous system. Levels are very high in the hypothalamus, limbic system, and prefrontal cortex. These brain regions process sexual cues, desire, and reward.

When bremelanotide activates MC4R, it is thought to raise dopamine release in the medial preoptic area (Both, Curr Sex Health Rep, 2017). This brain region is tied to sexual behavior across many mammal species. More dopamine there is believed to lower the threshold for arousal. The person then responds more readily to sexual cues that might otherwise be too weak in someone with HSDD.

Preclinical research by Pfaus et al. (J Sex Med, 2007) offered direct evidence for the CNS pathway. In female rat models, bremelanotide selectively increased sexual solicitation — the behaviors females use to start sexual contact. It did not change general movement or non-sexual behavior (Pfaus et al., PNAS, 2004).

This selectivity matters. It shows the compound targets sexual motivation pathways, not general CNS stimulation. That focus is what separates bremelanotide from non-specific stimulants or mood drugs. Those may affect sex only as a side effect.

MC1R: The Pigmentation Receptor

PT-141 actually binds MC1R most strongly. MC1R is the melanocyte-stimulating hormone receptor, found mainly in skin. When activated, it tells melanocytes to make melanin. That is why focal hyperpigmentation (localized skin darkening) is an observed PT-141 peptide side effect. This activity is a leftover from the compound's tanning-agent origins. For sexual dysfunction treatment, it is an unwanted side effect, not a benefit.

The pigmentation tends to be localized, not body-wide. It is more common with frequent, long-term use.

The Excitatory-Inhibitory Balance Model

Current models of HSDD point to an imbalance between excitatory and inhibitory neural pathways in the prefrontal cortex and limbic system. In women (and likely men) with HSDD, inhibitory signals dominate. These come mainly from serotonin, endogenous opioids, and endocannabinoids. Excitatory signals — from dopamine, norepinephrine, and melanocortins — fall behind. The result is less response to sexual cues and lower desire (Kingsberg et al., CNS Drugs, 2015).

Melanocortins, including bremelanotide, sit on the excitatory side. They are linked to appetitive sexual behavior. By activating these pathways through MC4R, PT-141 is thought to restore balance. That allows a normal desire response rather than a forced, artificial arousal.

This model explains a key point. The compound enhances the response to sexual cues rather than creating arousal out of nowhere. That distinction separates it from aphrodisiacs or recreational drugs.

How Is PT-141 Different From Viagra and Cialis?

The difference between PT-141 and PDE5 inhibitors like Viagra (sildenafil) and Cialis (tadalafil) is one of the most important ideas in sexual medicine. These drug classes target different parts of sexual function through different mechanisms. Anyone researching sexual health peptides needs to understand this.

The core contrast is simple. PDE5 inhibitors treat the physical mechanics of the sexual response. PT-141 treats the desire and arousal systems in the brain that start and sustain sexual motivation.

The practical takeaway is clear. PT-141 and PDE5 inhibitors solve different problems. Someone with normal desire but trouble getting or keeping an erection may benefit from a PDE5 inhibitor for erectile dysfunction. Someone with low desire or arousal — whatever their physical capacity — is the patient PT-141 was made for.

When both desire and physical function are impaired, the two mechanisms may work together rather than compete. Combined use has not been formally studied in clinical trials, however. This point matters most for PT-141 for women. PDE5 inhibitors show little effect in female sexual dysfunction, because female sexual response works differently.

The drug interaction profiles differ too. PDE5 inhibitors carry major warnings with nitrates and alpha-blockers, because of the risk of severe low blood pressure. PT-141 is broken down by peptidases, not CYP450 enzymes, so it has few drug interactions. A Phase I study (Clayton et al., Clin Ther, 2017) found no meaningful interaction between bremelanotide and alcohol. This further separates its safety profile from PDE5 inhibitors, which can cause stronger drops in blood pressure with alcohol in some people.

PT-141 for Women: RECONNECT Phase 3 Clinical Trial Results

The strongest evidence for PT-141 for women comes from the RECONNECT trials. These were two identical Phase 3 studies: randomized, double-blind, placebo-controlled, and multicenter. They formed the basis of the FDA approval (Kingsberg et al., Obstet Gynecol, 2019). They are the most rigorous studies ever run on PT-141. They give the clearest data on its efficacy and safety in women with hypoactive sexual desire disorder.

Study Design

The two trials (NCT02333071 and NCT02338960) enrolled 1,267 premenopausal women. All were diagnosed with acquired, generalized HSDD by DSM-IV-TR criteria. Participants were randomized 1:1 to bremelanotide 1.75 mg or placebo. They self-administered it under the skin as needed, at least 45 minutes before expected sexual activity. Treatment ran 24 weeks. They could take at most 12 doses per 4-week period and no more than one dose per 24 hours.

The mean age was 39 years. 85.6% identified as white, and 96.6% enrolled at U.S. sites. There were two coprimary endpoints. One was the change from baseline in the Female Sexual Function Index–Desire domain (FSFI-D) score. The other was the Female Sexual Distress Scale–Desire/Arousal/Orgasm (FSDS-DAO) item 13 score. Both were measured as the mean of monthly scores across the 24 weeks, versus placebo.

Efficacy Results

Both studies met their coprimary endpoints. This gave strong evidence that PT-141 improves both desire and distress in women with HSDD. Women on bremelanotide showed statistically significant improvements in sexual desire versus placebo. Treatment differences were +0.30 (P<.001) in Study 301, +0.42 (P<.001) in Study 302, and +0.35 (P<.001) in the pooled analysis. Distress related to low sexual desire also fell significantly: -0.37 (P<.001) in Study 301, -0.29 (P=.005) in Study 302, and -0.33 (P<.001) pooled.

The results held across both studies. That replication gave regulators the confidence they needed.

The effect sizes deserve context. In the pooled data, the effect size for improved sexual desire was 0.39 versus placebo. For reduced distress it was 0.27. For comparison, once-daily flibanserin (the other approved HSDD drug) showed effect sizes of 0.29–0.44 for desire and 0.24–0.44 for distress across three Phase 3 studies.

For more perspective, SSRIs for generalized anxiety disorder report placebo-relative effect sizes near 0.36 (Hidalgo et al., J Psychopharmacol, 2007). Many widely used psychiatric drugs land in a similar range. With PT-141, effects appeared by Week 4 (the first check) and held through all 24 weeks. In other words, tolerance to the drug's effect did not develop with continued use.

Long-Term Extension Data

Of the 856 patients who finished the core study, about 80% (684) joined the open-label extension. That included 87% of former placebo patients and 70% of former bremelanotide patients (Simon et al., Obstet Gynecol, 2019). The high sign-up among former placebo patients is telling. It suggests patients who saw the benefits of PT-141 peptide during the blinded phase actively wanted the active treatment.

The extension showed no new safety signals. The authors noted that gains in desire and distress held during extended use. One case of acute hepatitis appeared after about a year of use. It resolved fully after stopping the drug. A causal link could not be confirmed, and no other liver events occurred across the program.

PT-141 for Men: What the Research Shows

PT-141 is FDA-approved only for premenopausal women with HSDD. Still, the compound has been studied in men, and that male data is an important part of the research picture. Interest in PT-141 for men comes from its central mechanism. It targets desire at the neurological level, not just blood flow.

One point must be clear. PT-141 is not FDA-approved for men or for erectile dysfunction. Any male use is off-label, without completed Phase 3 clinical trials behind it. The idea of bremelanotide for men remains investigational.

Diamond et al. Phase I Trial (2004)

The most cited study on PT-141 for men is a Phase I trial by Diamond et al., published in the International Journal of Impotence Research (2004). It was randomized, double-blind, and placebo-controlled. It tested intranasal PT-141 in two groups. One was healthy men without visual sexual stimulation, to measure effects without erotic cues. The other was Viagra-responsive erectile dysfunction patients with visual sexual stimulation, to measure erectile response in a realistic setting.

The key findings were notable. Erectile responses were statistically significant at doses above 7 mg intranasally. Erections began within about 30 minutes of nasal spray use. The intranasal route showed a median Tmax of 0.50 hours — faster than the 1.0-hour Tmax of subcutaneous injection — and a half-life of 1.85–2.09 hours.

No maximum tolerated dose was found in the range tested. The most common side effects were flushing and nausea. The authors called PT-141 "a promising candidate for further evaluation as a treatment for male ED." That pointed to real potential for bremelanotide for men in the erectile dysfunction space.

Why PT-141 Was Not Approved for Men

Despite promising Phase I data, the program focused on female HSDD, not male ED. Several factors drove that choice. The male ED market was already dominated by effective oral PDE5 inhibitors (Viagra, Cialis, Levitra). These had known safety profiles, wide acceptance, and the convenience of pills.

PT-141's injection was seen as a big disadvantage there. Oral tablets were the standard of care, and patients were unlikely to switch to an injectable unless it worked far better. A PT-141 pill form was never developed, because peptides are poorly absorbed by mouth — enzymes in the gut break them down. On top of that, the unmet need looked much larger in female sexual dysfunction, where no on-demand option existed before Vyleesi.

The intranasal form first planned for men was later dropped. The subcutaneous injection proved more reliable and consistent in pharmacokinetic studies.

Future Prospects for Bremelanotide for Men

Whether PT-141 will ever be formally developed for men is still open. Its mechanism — raising desire through CNS melanocortin pathways — meets a need PDE5 inhibitors cannot. That includes male hypoactive sexual desire disorder and cases where erectile dysfunction comes with low libido.

Some clinicians note that PT-141 for men could fill a gap. Desire-based male sexual dysfunction has no FDA-approved treatment. Even so, running Phase 3 clinical trials for a second use would be costly and complex. No such trials are currently registered or publicly planned by Palatin Technologies or its licensees.

PT-141 Benefits: Complete Research Overview

The PT-141 benefits in the research span several categories. It helps to separate two types. FDA-approved benefits rest on Phase 3 clinical trials. Research-stage benefits rest on earlier-phase or preclinical data only. The overview below sorts PT-141 benefits by evidence level, so you can see what is proven versus what is still under study.

FDA-Approved Benefit: Increased Sexual Desire in Women with HSDD

The only FDA-approved benefit is treating acquired, generalized hypoactive sexual desire disorder in premenopausal women. The RECONNECT trials confirmed several primary benefits. Desire improved significantly (FSFI-D: +0.35 vs placebo, P<.001). Distress dropped significantly (FSDS-DAO: -0.33 vs placebo, P<.001). Satisfying sexual encounters rose 2.5-fold (25.0% vs 9.8%, P<.001, post hoc). The responder rate reached 58% versus 36% with placebo on the Global Assessment Questionnaire.

These benefits appeared within 4 weeks of starting treatment. They held over the full 24 weeks, with no sign of tachyphylaxis (tolerance).

Research-Stage Benefit: Erectogenic Effects in Men

Among research-stage benefits, Phase I data showed significant erectile responses in healthy men and ED patients at intranasal doses above 7 mg. Erections started within about 30 minutes. This fast effect, plus the compound's ability to enhance sexual desire centrally, suggests a dual mechanism. In theory it could complement — though not replace — existing ED treatments.

This is an early finding without Phase 3 confirmation. Formal development of PT-141 for men with ED has not been pursued.

Research-Stage Benefit: Central Arousal Enhancement

One of the most distinctive PT-141 benefits is its central mechanism. It enhances both desire and arousal in the brain, not through blood vessels. Preclinical studies showed selective facilitation of sexual solicitation in female rats, without changing general activity (Pfaus et al., PNAS, 2004). That points to specific modulation of sexual motivation, not broad stimulation.

This central pathway is unique among sexual dysfunction treatments. It may help most when dysfunction is mainly psychological or desire-based rather than physical.

Research-Stage Benefit: Dual-Gender Applicability

PT-141 is one of very few sexual function compounds with clinical evidence in both men and women. PDE5 inhibitors are male-only. Flibanserin is female-only. PT-141's mechanism — activating brain melanocortin receptors — is not sex-specific. The data is at different stages for each gender, but it supports meaningful effects of PT-141 in both. That makes PT-141 a unique compound in sexual dysfunction research and a valuable tool for studying the neuroscience of desire.

Research-Stage Benefit: Minimal Drug Interactions

PT-141's pharmacokinetics give it a real edge on drug interactions. Bremelanotide is broken down by peptidases through amide bond hydrolysis, not by cytochrome P450 enzymes. So it has little potential for pharmacokinetic drug-drug interactions. The alcohol study (Clayton et al., Clin Ther, 2017) and the overall program confirmed this, finding no clinically significant interactions.

Many HSDD patients take several medications. For them, this minimal-interaction profile is a real practical benefit.

PT-141 Dosage: FDA-Approved and Research Protocols

PT-141 dosage depends on the context. The FDA-approved product (Vyleesi) is one thing. The research-grade peptide is another. They differ in formulation, concentration, and dosing. The right PT-141 dosage depends on the route, the person's tolerance, and whether the use is the FDA-approved indication or off-label research.

FDA-Approved Dosage (Vyleesi)

The approved PT-141 dosage for Vyleesi is precise: 1.75 mg under the skin, via an autoinjection pen, at least 45 minutes before expected sexual activity. The label sets two limits. Do not use more than one dose in 24 hours. Do not exceed about 12 doses per month (roughly one every other day).

This dose came from Phase 2b dose-finding data (Clayton et al., Womens Health, 2016). That trial tested 0.75 mg, 1.25 mg, and 1.75 mg in 327 premenopausal women with HSDD. The 1.75 mg dose gave the best efficacy with acceptable safety, so it moved into the Phase 3 RECONNECT trials. The 0.75 mg dose did not beat placebo on the primary endpoint. The 1.25 mg dose fell in between, which supports a dose-response relationship.

Research Community Protocols

In the research community, off-label PT-141 dosing protocols for men and women often use a wider range than 1.75 mg. Common protocols start at 0.5–1.0 mg under the skin to test tolerance, especially for nausea. They then titrate up to 1.5–2.0 mg based on response.

The reason for a lower start is simple. Nausea appears to be dose-dependent, and some people respond well below 1.75 mg. Male protocols sometimes use slightly higher doses (1.0–2.0 mg under the skin). These are extrapolated from the Phase I intranasal data, where doses above 7 mg intranasally — a route with much lower bioavailability — produced significant erectile responses.

PT-141 Dosage for Women vs Men

There is no solid evidence that the best PT-141 dosage differs between men and women when injected under the skin. The 1.75 mg dose was set in the female HSDD population. No matching dose-finding studies exist for male subcutaneous use. The Phase I male study used intranasal doses of 7–20 mg, but intranasal bioavailability is far lower than subcutaneous, so those numbers are not directly comparable.

Community protocols for PT-141 for men often use similar subcutaneous doses (1.0–2.0 mg) to those used in women. Some male users report good responses at the higher end. The PT-141 dosage for women should follow the FDA protocol when possible, starting at 1.75 mg as the evidence-based dose.

PT-141 Dosage Calculator: Reconstitution Guide

Research-grade PT-141 usually comes as a freeze-dried (lyophilized) powder. Vials hold either 5 mg or 10 mg. This PT-141 dosage calculator section gives the reconstitution math for those sizes. You must reconstitute with bacteriostatic water before the PT-141 peptide injection can be given.

The amount of water you add sets the concentration. The concentration then sets the volume you need per dose. The tables below show reference calculations for common vial sizes and dose targets.

5 mg Vial Reconstitution

10 mg Vial Reconstitution

How to Use the PT-141 Dosage Calculator

To find any PT-141 dosage volume from a reconstituted vial, use one formula: Volume (mL) = Desired Dose (mg) ÷ Concentration (mg/mL). On a standard U-100 insulin syringe, each "unit" mark equals 0.01 mL. So multiply your volume by 100 to get the number of units to draw.

Here is an example. Say you reconstitute a 10 mg vial with 2.0 mL of bacteriostatic water. That gives a 5.0 mg/mL concentration. For a 1.75 mg dose: 1.75 ÷ 5.0 = 0.35 mL = 35 units.

When you reconstitute PT-141, inject the water slowly down the inner wall of the vial. Swirl gently to dissolve. Never shake the vial hard — that can denature the peptide and cut potency. The solution should look clear and colorless. Discard any vial with particles, cloudiness, or color.

Store reconstituted PT-141 at 2–8°C (refrigerator). Use it within 4–6 weeks for best potency, since peptides slowly break down even when cold.

PT-141 Nasal Spray vs PT-141 Peptide Injection

The PT-141 nasal spray has a real place in the compound's history. The earliest clinical trials — including the Diamond et al. Phase I trial in men — used an intranasal route. The first plan even envisioned a PT-141 nasal spray as the main commercial form for both sexes.

Knowing the history, evidence, and limits of the PT-141 nasal spray versus the PT-141 peptide injection helps researchers compare delivery routes.

Clinical Evidence for Intranasal PT-141

In the Diamond et al. (2004) study, the nasal spray showed dose-dependent absorption. The median Tmax was 0.50 hours, faster than the 1.0-hour Tmax of subcutaneous injection. The half-life was 1.85–2.09 hours. Erectile responses were significant at doses above 7 mg intranasally, and the first erection came within about 30 minutes.

But intranasal bioavailability is much lower than subcutaneous, which is 100%. So you need far higher intranasal doses to reach the same systemic exposure. That is why the effective intranasal dose (>7 mg) is so much larger than the effective subcutaneous dose (1.75 mg).

Why the PT-141 Nasal Spray Was Abandoned for FDA Approval

Nasal delivery is convenient, but the program still moved from the nasal spray to the PT-141 peptide injection. Several reasons drove this. First, intranasal absorption varied a lot — between people, and even between doses in the same person. That made pharmacokinetics less predictable and dose-response inconsistent.

Second, the higher intranasal doses came with greater blood pressure effects than the lower subcutaneous doses. That raised cardiovascular safety concerns at the doses needed to work. Third, the subcutaneous autoinjection pen gave the most consistent pharmacokinetic profile for approval, which was essential to prove reliable efficacy in the Phase 3 trials.

Current Research PT-141 Nasal Spray Products

Some research peptide suppliers offer PT-141 in pre-made nasal spray devices. These often deliver a set concentration of reconstituted bremelanotide in metered doses. They are not FDA-approved and are sold for research only. Keep two things in mind. The nasal route needs much higher doses than the PT-141 peptide injection to match systemic exposure. And absorption can shift with nasal congestion, mucosal condition, recent nasal products, and spray technique.

For the most predictable, research-validated dosing, the subcutaneous PT-141 peptide injection remains the gold standard. It offers 100% bioavailability and a consistent pharmacokinetic profile. A PT-141 pill form has never been made, because peptides like bremelanotide are broken down in the gut and cannot be absorbed well by mouth.

PT-141 Side Effects: What Are the Risks?

PT-141 has one of the best-characterized PT-141 side effects profiles of any research peptide. That is thanks to the large Phase 2 and Phase 3 clinical trials run during FDA approval. Knowing these PT-141 side effects is key to risk assessment. The RECONNECT trials enrolled 1,247 women in the safety population. That gives strong data on how often side effects occur, how bad they are, when they start, how long they last, and how to manage them.

Common Side Effects (RECONNECT Trial Data)

Managing Nausea: The Primary Tolerability Challenge

Nausea is by far the biggest tolerability issue among PT-141 side effects. It affected 40% of women in the trials. But several factors soften that number and point to ways to manage it. First, the nausea was mild to moderate in about 98% of cases. It resolved on its own without medical care.

The median onset was about 30 minutes after dosing. The median duration was 2.4 hours. Second, only 8.1% of patients stopped treatment because of nausea. So most affected patients found it manageable and kept going to get the improved sexual desire benefits.

Third, the nausea tended to come and go, not with every dose. Antiemetic use cut later nausea rates to about 5% (versus about 15% without). Fourth, community reports suggest starting lower helps. A 0.5–1.0 mg start, rather than the full 1.75 mg, may cut early nausea while still improving desire.

Blood Pressure Effects

PT-141 causes small, brief increases in blood pressure: about 3 mmHg systolic and 2 mmHg diastolic. These peak within 2–4 hours and return to baseline within 8–10 hours. Heart rate drops at the same time, so there is no net rise in heart workload. The as-needed dosing pattern means these small changes do not build up over time.

Still, caution is wise for some patients. Anyone with high blood pressure that is not controlled, or with cardiovascular disease, should be careful. The Vyleesi label advises checking blood pressure in patients with a history of cardiovascular disease. Clinicians should discuss this increase in blood pressure — one of the PT-141 peptide side effects — with patients before starting.

Hyperpigmentation

Focal hyperpigmentation (localized skin darkening) has been reported uncommonly among PT-141 side effects. It comes from MC1R activation driving melanocyte activity and melanin — the same mechanism that first made PT-141 useful as a tanning agent. It is usually cosmetic and harmless. Some long-term users report darkening around the face, gums, breasts, or injection site.

This PT-141 peptide side effect may be stronger in people with darker skin and in those who use the compound often over long periods. In trials, hyperpigmentation was uncommon and did not cause anyone to stop treatment.

Contraindications

The Vyleesi label lists specific contraindications. The compound should not be used in patients with uncontrolled hypertension — that is, poorly controlled high blood pressure — or with known cardiovascular disease, because of the transient rise in blood pressure. It is also not recommended in pregnancy or breastfeeding, since reproductive safety data is limited.

Bremelanotide should not be used with naltrexone or other melanocortin receptor antagonists that could blunt its effect. Importantly, the trials found no clinically significant effects on labs, ECG, weight, depression, or suicidal thoughts. No deaths occurred in either RECONNECT study.

PT-141 Pharmacokinetics and Duration of Action

PT-141's pharmacokinetics are well studied. Multiple trials measured them across both subcutaneous and intranasal routes. These numbers help researchers and clinicians predict onset, peak effect, duration, and dosing intervals.

Here is what these numbers mean in practice. PT-141 reaches peak effect about an hour after a subcutaneous PT-141 peptide injection, with 100% of the dose reaching the bloodstream. The 2.7-hour half-life means plasma levels drop by about half every 2.7 hours. So meaningful activity lasts roughly 4–6 hours, then fades.

After about 5 half-lives (roughly 13.5 hours), the compound is essentially gone. That fits the recommended 24-hour minimum between doses.

The low drug-interaction risk is a real advantage. It comes from peptidase metabolism rather than CYP450 metabolism. Many small-molecule drugs are processed by liver enzymes and can interact with other drugs. Bremelanotide is not. Ubiquitous peptidases break it down by simple amide bond hydrolysis.

As a result, it is unlikely to interact with other medications the patient takes. That includes oral contraceptives, antidepressants, antihypertensives, and other common drugs in this population.

Is PT-141 Legal? FDA Status and Regulatory Considerations

The PT-141 legal status has two sides: the pharmaceutical product and the research peptide. Different rules govern each. Researchers, clinicians, and interested individuals need to know the difference.

Vyleesi (Pharmaceutical Product)

Bremelanotide as Vyleesi is a prescription drug, FDA-approved since June 21, 2019. It is legally available in the U.S. with a valid prescription for acquired, generalized HSDD in premenopausal women. It is a prescription drug, not a controlled substance. So it has no DEA schedule and no controlled-substance prescribing limits.

Off-label use of Vyleesi — for male patients or postmenopausal women — is at the physician's discretion. Off-label prescribing is legal in the U.S. when the physician judges it medically appropriate based on the evidence.

Research-Grade PT-141 Peptide

Research-grade bremelanotide is sold by research chemical suppliers. It is labeled "for research purposes only" and "not for human consumption." It sits in a legal gray area. It is legal to buy and possess for legitimate research in most places, but it is not FDA-approved for self-use. The gap between pharmaceutical Vyleesi and research-grade peptide matters for both safety and regulation. Vyleesi is made under cGMP with strict quality controls. Research-grade peptide quality varies by supplier.

The research-grade product goes through different manufacturing and quality control than pharmaceutical bremelanotide. The two are not interchangeable.

International Considerations

Bremelanotide is not a controlled substance in most countries. It is not on the WADA Prohibited List for athletes, though athletes should still check their sport's rules. Regulatory status does vary by country, so verify local rules on research peptides. In some countries, PT-141 may be available through compounding pharmacies with a prescription. In others it may be restricted or unavailable.

The European Medicines Agency has not approved bremelanotide. So pharmaceutical-grade Vyleesi is generally unavailable in Europe, though research-grade bremelanotide may be reachable through international suppliers.

PT-141 Peptide Storage and Handling

Proper storage keeps PT-141 potent and dosing accurate over the life of each vial. As a synthetic peptide, bremelanotide can degrade through hydrolysis, oxidation, and heat. Storage conditions strongly affect how long it stays active and stable.

Lyophilized (Unreconstituted) PT-141

In freeze-dried powder form, PT-141 is fairly stable. Store unreconstituted vials at -20°C (freezer) for long-term storage (24 months or more). Use 2–8°C (refrigerator) for medium-term storage (6–12 months). At room temperature (15–25°C), the powder stays stable for shorter periods — weeks to a few months — so brief exposure during shipping is generally fine.

Keep vials away from direct light and moisture. Make sure the rubber stopper seal stays intact to block humidity. The freeze-dried form is the most stable state, so keep it that way until you need to reconstitute.

Reconstituted PT-141

Once mixed with bacteriostatic water, the peptide degrades faster, because water promotes hydrolysis of the amide bonds. Store reconstituted PT-141 at 2–8°C (refrigerator) and use it within 4–6 weeks for best potency. Do not freeze it — ice crystals can damage the peptide.

If you use plain sterile water (without the preservative benzyl alcohol), use the solution within 48–72 hours. That limits the risk of microbial contamination, since plain sterile water has no ongoing preservative. Always use clean technique when drawing from a multi-use vial. Swab the rubber stopper with alcohol before each withdrawal.

Signs of Degradation

A properly reconstituted PT-141 solution should be clear, colorless, and free of particles. Discard any vial that turns cloudy, shows particles, changes color (yellow or brown), or smells off. These signs may mean aggregation, oxidation, contamination, or heat damage. If you see them, the potency and safety cannot be trusted, so reconstitute a fresh vial.

Buying PT-141 Peptide for Research: Quality and Safety

When you buy research-grade PT-141, quality checks matter. It is a synthetic peptide that can degrade, get contaminated, or be under-dosed if made or handled poorly. Good versus bad PT-141 can be the difference between reliable results and wasted time.

Certificate of Analysis (CoA)

Every reputable supplier should provide a batch-specific Certificate of Analysis from an independent, accredited lab. The CoA should include several items: HPLC purity (target ≥98% for research-grade bremelanotide), mass spectrometry confirming identity (expected weight ~1,025 Da for the free base), endotoxin testing (LAL assay, important for injectables), and appearance/solubility data.

Ask for the CoA before you buy. Confirm it matches the exact batch you will receive, not a generic report from another lot.

Supplier Selection Criteria

Reliable suppliers are transparent about manufacturing and peptide synthesis. They offer responsive, knowledgeable support. They keep quality consistent across batches, which you can verify through multiple CoAs. They label products with clear research-use disclaimers. Look for an established reputation, verified third-party testing from recognized labs, proper cold-chain shipping (ice packs, insulated packaging, or dry ice), and clear labels showing peptide content, lot number, manufacturing date, and expiration date.

Avoid suppliers that make medical claims, suggest specific therapeutic uses, guarantee results, or refuse to share a Certificate of Analysis.

Red Flags to Avoid

Several warning signs point to an unreliable supplier. Prices far below market may mean under-dosing or contamination. Watch for no CoA, or only a generic CoA not tied to a batch. Be wary of medical claims or therapeutic-use suggestions on the site. Note the lack of a verifiable business address or contact details. Check for packaging without lot numbers or expiration dates. And avoid sellers with no cold-chain shipping for temperature-sensitive peptides.

Research-grade bremelanotide from reputable makers costs within a consistent market range. Prices that look too good to be true usually are.

Frequently Asked Questions About PT-141 Peptide